Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation

Oncotarget

Volumn 6, Issue 10, 2015, Pages 7866-7879

  Jiang, Nan ^a   Chen, Wen Jie ^a   Zhang, Jian Wen ^a   Xu, Chi ^a   Zeng, Xian Cheng ^b   Zhang, Tong ^a   Li, Yang ^a   Wang, Guo Ying ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; MiR 432; Proliferation; Wnt catenin

Indexed keywords

BETA CATENIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MICRORNA; MICRORNA 432; PEPTIDES AND PROTEINS; PROTEIN PYGO2; PROTEIN TRIM29; UNCLASSIFIED DRUG; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN; MIRN432 MICRORNA, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL NUCLEUS; CELL PROLIFERATION; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; WNT SIGNALING PATHWAY; XENOGRAFT;

ANIMALS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DOWN-REGULATION; HEP G2 CELLS; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84928402119     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3492     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010; 127(12):2893-2917.
3. Bosch FX, Ribes J, Diaz M and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127(5 Suppl 1):S5-S16.
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of hepatology. 2006; 45(4):529-538.
5. Nguyen VT, Law MG and Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. Journal of viral hepatitis. 2009; 16(7):453-463.
6. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, de la Monte S and Wands JR. Oncogenic role of the frizzled-7/betacatenin pathway in hepatocellular carcinoma. Journal of hepatology. 2005; 43(5):854-862.
7. Polakis P. Wnt signaling and cancer. Genes & development. 2000; 14(15):1837-1851.
8. Kondo Y, Kanai Y, Sakamoto M, Genda T, Mizokami M, Ueda R and Hirohashi S. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Japanese journal of cancer research: Gann. 1999; 90(12):1301-1309.
9. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA and Liu W. Mutational spectrum of betacatenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002; 21(31):4863-4871.
10. Kim YD, Park CH, Kim HS, Choi SK, Rew JS, Kim DY, Koh YS, Jeung KW, Lee KH, Lee JS, Juhng SW and Lee JH. Genetic alterations of Wnt signaling pathwayassociated genes in hepatocellular carcinoma. Journal of gastroenterology and hepatology. 2008; 23(1):110-118.
11. Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, Waldhor T, Peck-Radosavljevic M, Beug H and Mikulits W. Nuclear betacatenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. The American journal of pathology. 2010; 176(1):472-481.
12. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES and Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. The American journal of pathology. 1999; 155(3):703-710.
13. Cui J, Zhou X, Liu Y, Tang Z and Romeih M. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. Journal of gastroenterology and hepatology. 2003; 18(3):280-287.
14. Bengochea A, de Souza MM, Lefrancois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P, Scoazec JY, Vitvitski L and Merle P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. British journal of cancer. 2008; 99(1):143-150.
15. Li Y, Lu W, He X, Schwartz AL and Bu G. LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution. Oncogene. 2004; 23(56):9129-9135.
16. Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H and Bienz M. A new nuclear component of the Wnt signalling pathway. Nature cell biology. 2002; 4(5):367-373.
17. Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M and Simeone DM. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer cell. 2009; 15(3):207-219.
18. Tung EK, Wong BY, Yau TO and Ng IO. Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. PloS one. 2012; 7(5):e36565.
19. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, Murone M, Zullig S and Basler K. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell. 2002; 109(1):47-60.
20. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-297.
21. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nature reviews Cancer. 2006; 6(11):857-866.
22. Gregory RI and Shiekhattar R. MicroRNA biogenesis and cancer. Cancer research. 2005; 65(9):3509-3512.
23. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nature reviews Cancer. 2006; 6(4):259-269.
24. Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW and Ahn WS. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug design, development and therapy. 2014; 8:293-314.
25. Yao T, Rao Q, Liu L, Zheng C, Xie Q, Liang J and Lin Z. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer. Virology journal. 2013; 10:175.
26. D'Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, Fedele M, Croce CM, Trouillas J and Fusco A. Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. The Journal of clinical endocrinology and metabolism. 2012; 97(7):E1128-1138.
27. Das E and Bhattacharyya NP. MicroRNA-432 contributes to dopamine cocktail and retinoic acid induced differentiation of human neuroblastoma cells by targeting NESTIN and RCOR1 genes. FEBS letters. 2014; 588(9):1706-1714.
28. Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, et al. MicroRNAmediated loss of ADAR1 in metastatic melanoma promotes tumor growth. The Journal of clinical investigation. 2013; 123(6):2703-2718.
29. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-480.
30. Clevers H and Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012; 149(6):1192-1205.
31. Moon RT, Kohn AD, De Ferrari GV and Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nature reviews Genetics. 2004; 5(9):691-701.
32. Barker N and Clevers H. Mining the Wnt pathway for cancer therapeutics. Nature reviews Drug discovery. 2006; 5(12):997-1014.
33. Jiang L, Yang YD, Fu L, Xu W, Liu D, Liang Q, Zhang X, Xu L, Guan XY, Wu B, Sung JJ and Yu J. CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma. Oncotarget. 2014; 5(17):7663-7676.
34. Wong CM, Fan ST and Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 2001; 92(1):136-145.
35. Tolwinski NS, Wehrli M, Rives A, Erdeniz N, DiNardo S and Wieschaus E. Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta activity. Developmental cell. 2003; 4(3):407-418.
36. Cong F, Schweizer L and Varmus H. Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development. 2004; 131(20):5103-5115.
37. Hawthorn L, Stein L, Panzarella J, Loewen GM and Baumann H. Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung. Lung cancer. 2006; 53(2):129-142.
38. Kosaka Y, Inoue H, Ohmachi T, Yokoe T, Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Annals of surgical oncology. 2007; 14(9):2543-2549.
39. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K and Orntoft TF. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer research. 2004; 64(11):4040-4048.
40. Glebov OK, Rodriguez LM, Soballe P, DeNobile J, Cliatt J, Nakahara K and Kirsch IR. Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006; 15(11):2253-2262.
41. Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, Lake BB and Kao KR. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(7 Pt 1):2216-2223.
42. Andrews PG, Lake BB, Popadiuk C and Kao KR. Requirement of Pygopus 2 in breast cancer. International journal of oncology. 2007; 30(2):357-363.
43. Wang ZX, Chen YY, Li BA, Tan GW, Liu XY, Shen SH, Zhu HW and Wang HD. Decreased pygopus 2 expression suppresses glioblastoma U251 cell growth. Journal of neuro-oncology. 2010; 100(1):31-41.
44. Skawran B, Steinemann D, Weigmann A, Flemming P, Becker T, Flik J, Kreipe H, Schlegelberger B and Wilkens L. Gene expression profiling in hepatocellular carcinoma: upregulation of genes in amplified chromosome regions. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2008; 21(5):505-516.